Developer docs
API playgroundTry for free, no card

Search company profiles

Noetik

Full company profile

uuid00005t4

Namestring
Noetik
Legal namestring
Noetik Inc.
Websiteurl
noetik.ai
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Noetik is an AI-native biotechnology company founded in 2023 by Ron Alfa (former SVP, Head of Research at Recursion) and Jacob Rinaldi, headquartered in South San Francisco. The company's core platform integrates three layers: (1) an in-house Human Data factory that generates paired multimodal spatial omics measurements (H&E, multiplex protein panels, whole spatial transcriptomes, and whole exome sequencing) from tumor resections using patent-pending tissue microarray (TMA) processes, currently at 2.9PB of data, 450M cells, 196,000 cores, and 4,500+ patients; (2) a family of foundation models trained on that data, including the OCTO "world model," OCTO-VirtualCell (OCTO-vc) virtual cell simulator, and TARIO-2 response predictor; and (3) downstream applications such as the Perturb-map in vivo functional genomics platform and the Celleporter interactive visualization tool.

The technology uses a custom structured multimodal masking objective on spatially aligned tokens across modalities, with the OCTO base model pre-trained on 20B tokens across 128 GPUs and the OCTO-vc model reaching 1.5B parameters on approximately 200M cells. TARIO-2 uniquely infers spatial transcriptomic-grade response prediction from routine pretreatment H&E slides alone, which is the primary commercial artifact.

Noetik monetizes the platform through multi-year, non-exclusive enterprise licensing of foundation models to pharma (anchor reference: a five-year, $50M+ upfront deal with GSK for OCTO-VC in NSCLC and colorectal cancer) and strategic co-development collaborations with biotech (e.g., Agenus for predictive biomarkers on BOT/BAL immuno-oncology). Pricing is bespoke and quote-based; no self-serve or marketplace exists. A pre-revenue internal cancer therapeutics pipeline is also being built out under an EVP of Therapeutics. The company has approximately 30 employees as of mid-2025 and is backed by DCVC, Polaris Partners, Khosla Ventures, and a syndicate of life-sciences-focused investors following a $14M seed (September 2023) and $40M Series A (August 2024).

Short descriptiontext

Noetik is an AI-native biotechnology company building multimodal transformer foundation models (OCTO, OCTO-vc, TARIO-2) trained on proprietary spatial tumor data to predict cancer patient treatment response, licensing the models and biomarkers to pharma (GSK, Agenus) while developing an internal therapeutics pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI foundation models, spatial omics analytics, biomarker discovery, cancer therapeutics AI, computational pathology
Product category
AI Foundation Models for Oncology
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Foundation model licensing to pharma
TypeLicensing Royalties
Description

Multi-year non-exclusive licensing of AI foundation models (e.g., five-year, $50M upfront plus near-term milestones deal with GSK for OCTO-VC models in NSCLC and colorectal cancer). Revenue recognized upfront and through milestone payments tied to research and commercial progress.

businesswire.com
2Research collaboration and biomarker development
TypeProfessional Services
Description

Strategic collaborations with biotech/pharma (e.g., Agenus) to develop AI-enabled predictive biomarkers for specific therapeutic programs, with exclusive rights for the partner to apply the resulting biomarker insights in drug development and commercialization.

businesswire.com
3Internal therapeutics pipeline (pre-revenue)
TypeSubscription Recurring
Description

Internal cancer therapeutics pipeline, led by EVP of Therapeutics, advancing programs from AI-driven discovery toward early clinical development. Not yet generating product revenue.

biospace.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Pricing details1 tier
1Enterprise licensing of foundation AI models (e.g., OCTO-VC virtual cell models for NSCLC and colorectal cancer) to pharma partners via multi-year, non-exclusive licenses with upfront payments and milestone-based economics.
ModelOtherBilling cadenceMulti-year contract
Notes

GSK deal reported as $50M upfront plus near-term milestones over five years (January 2026). Total contract value described as $50M+. Quote-based / not publicly disclosed.

businesswire.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1OCTO
Description

Oncology Counterfactual Therapeutics Oracle — Noetik's first foundation model (world model) for cancer biology, a multimodal transformer-based model trained on spatially aligned multiplex protein, gene expression, DNA sequencing, and H&E data.

noetik.ai
+4 more records
Core offering1 text field

Noetik develops and licenses AI foundation models for oncology drug discovery, trained on proprietary in-house generated multimodal spatial omics datasets from thousands of patient tumors. Its core products (OCTO, OCTO-vc, TARIO-2) enable prediction of cancer patient treatment response, identification of novel therapeutic targets through counterfactual virtual cell simulations, and image-based patient stratification from routine H&E pathology slides. The company monetizes these models through multi-year enterprise licensing agreements with pharmaceutical and biotechnology companies, supported by an integrated wet-lab data factory and in vivo Perturb-map validation platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 64% response rate vs 9% in remaining cohort for BOT+BAL in MSS mCRC (no active liver metastases), with overall survival hazard ratio of 0.18, in a retrospective study of 113 patients using TARIO-2 on routine pretreatment H&E images.
+4 more records
Product overview1 text field

Noetik operates an integrated AI-native drug discovery platform consisting of three interconnected pillars: (1) a proprietary Human Data layer that generates large-scale, spatially aligned multimodal tumor datasets (H&E, multiplex protein, spatial transcriptomics, WES) from thousands of patients in-house; (2) a suite of Foundation Models trained on that data — the OCTO world model, the OCTO-vc (virtual cell) model, the TARIO-2 therapeutic response predictor, and the Celleporter visualization interface; and (3) Applications that translate model outputs into concrete drug development outcomes, including the Perturb-map in vivo functional genomics platform for target validation and biomarker discovery. The platform is monetized both by out-licensing foundation models to pharma (e.g., the GSK OCTO-VC deal) and through research collaborations (e.g., Agenus BOT/BAL biomarker work).

Product and service4 records
1OCTO (Oncology Counterfactual Therapeutics Oracle)
CategoryFoundation Model (core platform)
Description

Noetik's first-in-class world model for cancer biology: a massively multimodal transformer pretrained on spatially aligned H&E, multiplex protein, spatial transcriptomics, and WES data via structured multimodal masking. Capable of simulating 16-channel protein images from heavily masked prompts and running counterfactual perturbation simulations to identify drug targets and predict therapeutic response. Designed to be licensed to pharmaceutical R&D organizations for indication-specific use.

2OCTO-VirtualCell (OCTO-vc)
CategoryFoundation Model (core platform)
Description

Next-generation virtual cell foundation model trained on ~40M cells (later scaled to ~200M) across many cancer indications. Simulates spatially resolved single-cell gene expression at arbitrary positions in real patient tissue, enabling high-fidelity prediction of thousands of genes in response to changes in biological context. Used to stratify patient populations and identify therapy resistance mechanisms (e.g., KRAS/STK11). Licensed to GSK under a five-year, $50M+ upfront non-exclusive license for NSCLC and CRC research.

3TARIO-2
CategoryFoundation Model (response predictor)
Description

Multimodal AI foundation model that predicts patient response and survival outcomes to next-generation immune checkpoint inhibitor combinations (e.g., Agenus's BOT+BAL) using only routine pretreatment H&E pathology images. Trained on thousands of samples across 19 cancer types and paired with high-resolution spatial transcriptomics during training. Outperformed leading pathology AI tools in retrospective MSS mCRC validation (64% vs. 9% response rate; HR 0.18 for OS).

4Perturb-map
CategoryIn Vivo Functional Genomics Platform
Description

High-throughput in vivo perturbation platform that introduces hundreds of tumor subpopulations with unique mutations (suggested by Noetik's models) into a single mouse, then spatially resolves their impact on the tumor microenvironment. Used to validate AI-generated therapeutic hypotheses, study tumor-immune interactions, and map how mutations affect response to immune checkpoint blockade. Initial dataset maps >600 perturbations on tumor immunotypes.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-24
Description

Expansion of an existing collaboration to advance AI-driven tissue foundational models for translational and therapeutic applications in oncology. Builds on a prior study of more than 3,500 patient samples using Bruker's CosMx Spatial Molecular Imager, with Noetik now imaging thousands of additional patients to train its models toward one billion spatially resolved human cells. Supports Noetik's OCTO series and Oncology Counterfactual Therapeutics Oracle virtual cell models.

Strategic tierFlagship / Anchor PartnershipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-08
Description

Five-year strategic collaboration and non-exclusive licensing agreement granting GSK access to Noetik's OCTO-VC virtual cell foundation models for non-small cell lung cancer (NSCLC) and colorectal cancer research. Deal valued at $50M upfront plus near-term milestones. Combines GSK's tumor immunology expertise with Noetik's spatial biology platform. Described as the first substantial pure-play AI licensing deal in the TechBio sector and a potential template for AI infrastructure licensing in biopharma. Noetik retains the right to license OCTO-VC to other drug developers.

Strategic tierCore / FlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

Research collaboration to develop AI-enabled predictive biomarkers for Agenus's botensilimab (BOT) and balstilimab (BAL) immuno-oncology treatments using Noetik's OCTO virtual cell foundation model (1.5B parameters, trained on multimodal spatial data from nearly 200M tumor and immune cells). Spans colorectal, lung, ovarian, and sarcoma cancers. Agenus receives exclusive rights to apply resulting biomarker insights in drug development and commercialization. Resulted in ASCO 2026 retrospective data showing 64% response rate vs 9% in TARIO-2-identified BOT+BAL subgroup in MSS mCRC without active liver metastases.

4Khosla Ventures
noetik.ai
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-native biotechnology company combining high-throughput biology with foundation-model-style ML to accelerate drug discovery. Noetik's two co-founders (Ron Alfa and Jacob Rinaldi) are both former Recursion leaders, making it the closest conceptual and operational analogue in the public TechBio space.

TypeDirect peer
Description

ML-driven drug discovery company combining induced pluripotent stem cell biology with foundation models and large-scale data generation. Overlaps with Noetik in using proprietary wet-lab data to train ML models for oncology and other indications, and competes for similar pharma partnerships and talent.

TypeDirect peer
Description

Pioneer of generative biology foundation models that learn the language of proteins and apply it to therapeutic design. Directly comparable to Noetik's OCTO family of multimodal foundation models, and similarly targets pharma partnerships and internal therapeutics programs.

TypeDirect peer
Description

AI-for-oncology and biopharma company that builds foundation models on multimodal patient data (pathology, omics, clinical) and partners with pharma on biomarker, stratification, and trial-enrichment use cases. Closely parallels Noetik's TARIO-2 thesis and pharma-licensing GTM.

TypeDirect peer
Description

AI-driven precision medicine company that combines generative chemistry with patient-derived data for drug design and selection. Comparable to Noetik in selling AI capabilities to large pharma partners and using data-driven approaches to oncology drug development.

TypeDirect peer
Description

AI-pathology company that builds foundation models on histopathology images for biomarker discovery, patient stratification, and pharma partnerships. Closely mirrors Noetik's TARIO-2 image-based response prediction approach and pathology-AI focus.

7Tempus Labs
TypeBroad incumbent
Description

Large, established AI-powered precision medicine company with massive multimodal oncology data (DNA, RNA, imaging, clinical) and extensive pharma services. A broad incumbent in the same oncology AI/data space Noetik targets, with a much larger scale and broader product portfolio.

TypeDirect peer
Description

Generative AI drug creation company combining foundation models for proteins with a high-throughput wet lab. Overlaps with Noetik in building proprietary data + foundation models to enable new therapeutics, and in pursuing both internal pipeline and pharma collaborations.

TypeDirect peer
Description

AI-drug discovery company that builds knowledge graphs and ML models to identify novel targets and indications, including in oncology. Comparable in combining AI/ML with pharma partnerships and pursuing precision-medicine applications in cancer.

TypeEmerging player
Description

AI-driven oncology company using machine learning on genomic and clinical data to develop and reposition cancer therapies, with an emphasis on response prediction. Less capital-intensive than Noetik but pursues a similar AI-for-oncology-therapeutics thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Noetik

AI Foundation Models for Oncologynoetik.ai

Noetik is an AI-native biotechnology company building multimodal transformer foundation models (OCTO, OCTO-vc, TARIO-2) trained on proprietary spatial tumor data to predict cancer patient treatment response, licensing the models and biomarkers to pharma (GSK, Agenus) while developing an internal therapeutics pipeline.

What Noetik does

Noetik is an AI-native biotechnology company founded in 2023 by Ron Alfa (former SVP, Head of Research at Recursion) and Jacob Rinaldi, headquartered in South San Francisco. The company's core platform integrates three layers: (1) an in-house Human Data factory that generates paired multimodal spatial omics measurements (H&E, multiplex protein panels, whole spatial transcriptomes, and whole exome sequencing) from tumor resections using patent-pending tissue microarray (TMA) processes, currently at 2.9PB of data, 450M cells, 196,000 cores, and 4,500+ patients; (2) a family of foundation models trained on that data, including the OCTO "world model," OCTO-VirtualCell (OCTO-vc) virtual cell simulator, and TARIO-2 response predictor; and (3) downstream applications such as the Perturb-map in vivo functional genomics platform and the Celleporter interactive visualization tool.

The technology uses a custom structured multimodal masking objective on spatially aligned tokens across modalities, with the OCTO base model pre-trained on 20B tokens across 128 GPUs and the OCTO-vc model reaching 1.5B parameters on approximately 200M cells. TARIO-2 uniquely infers spatial transcriptomic-grade response prediction from routine pretreatment H&E slides alone, which is the primary commercial artifact.

Noetik monetizes the platform through multi-year, non-exclusive enterprise licensing of foundation models to pharma (anchor reference: a five-year, $50M+ upfront deal with GSK for OCTO-VC in NSCLC and colorectal cancer) and strategic co-development collaborations with biotech (e.g., Agenus for predictive biomarkers on BOT/BAL immuno-oncology). Pricing is bespoke and quote-based; no self-serve or marketplace exists. A pre-revenue internal cancer therapeutics pipeline is also being built out under an EVP of Therapeutics. The company has approximately 30 employees as of mid-2025 and is backed by DCVC, Polaris Partners, Khosla Ventures, and a syndicate of life-sciences-focused investors following a $14M seed (September 2023) and $40M Series A (August 2024).

Noetik firmographics

Firmographics
Name
Noetik
Legal name
Noetik Inc.
Website
https://noetik.ai
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
Noetik is an AI-native biotechnology company building multimodal transformer foundation models (OCTO, OCTO-vc, TARIO-2) trained on proprietary spatial tumor data to predict cancer patient treatment response, licensing the models and biomarkers to pharma (GSK, Agenus) while developing an internal therapeutics pipeline.
Ownership category
akta.pro rank

Where Noetik is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Noetik business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Foundation model licensing to pharma: Multi-year non-exclusive licensing of AI foundation models (e.g., five-year, $50M upfront plus near-term milestones deal with GSK for OCTO-VC models in NSCLC and colorectal cancer). Revenue recognized upfront and through milestone payments tied to research and commercial progress.
  2. Research collaboration and biomarker development: Strategic collaborations with biotech/pharma (e.g., Agenus) to develop AI-enabled predictive biomarkers for specific therapeutic programs, with exclusive rights for the partner to apply the resulting biomarker insights in drug development and commercialization.
  3. Internal therapeutics pipeline (pre-revenue): Internal cancer therapeutics pipeline, led by EVP of Therapeutics, advancing programs from AI-driven discovery toward early clinical development. Not yet generating product revenue.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise licensing of foundation AI models (e.g., OCTO-VC virtual cell models for NSCLC and colorectal cancer) to pharma partners via multi-year, non-exclusive licenses with upfront payments and milestone-based economics.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Noetik product offering

Product offering

Core offering

Noetik develops and licenses AI foundation models for oncology drug discovery, trained on proprietary in-house generated multimodal spatial omics datasets from thousands of patient tumors. Its core products (OCTO, OCTO-vc, TARIO-2) enable prediction of cancer patient treatment response, identification of novel therapeutic targets through counterfactual virtual cell simulations, and image-based patient stratification from routine H&E pathology slides. The company monetizes these models through multi-year enterprise licensing agreements with pharmaceutical and biotechnology companies, supported by an integrated wet-lab data factory and in vivo Perturb-map validation platform.

Product overview

Noetik operates an integrated AI-native drug discovery platform consisting of three interconnected pillars: (1) a proprietary Human Data layer that generates large-scale, spatially aligned multimodal tumor datasets (H&E, multiplex protein, spatial transcriptomics, WES) from thousands of patients in-house; (2) a suite of Foundation Models trained on that data — the OCTO world model, the OCTO-vc (virtual cell) model, the TARIO-2 therapeutic response predictor, and the Celleporter visualization interface; and (3) Applications that translate model outputs into concrete drug development outcomes, including the Perturb-map in vivo functional genomics platform for target validation and biomarker discovery. The platform is monetized both by out-licensing foundation models to pharma (e.g., the GSK OCTO-VC deal) and through research collaborations (e.g., Agenus BOT/BAL biomarker work).

Differentiator

Problem solved

Functional benefit

Brands

  • OCTO: Oncology Counterfactual Therapeutics Oracle — Noetik's first foundation model (world model) for cancer biology, a multimodal transformer-based model trained on spatially aligned multiplex protein, gene expression, DNA sequencing, and H&E data.
  • OCTO-VirtualCell (OCTO-VC)
  • Celleporter
  • TARIO-2
  • Perturb-map

Products and services

  • OCTO (Oncology Counterfactual Therapeutics Oracle) Noetik's first-in-class world model for cancer biology: a massively multimodal transformer pretrained on spatially aligned H&E, multiplex protein, spatial transcriptomics, and WES data via structured multimodal masking. Capable of simulating 16-channel protein images from heavily masked prompts and running counterfactual perturbation simulations to identify drug targets and predict therapeutic response. Designed to be licensed to pharmaceutical R&D organizations for indication-specific use.
  • OCTO-VirtualCell (OCTO-vc) Next-generation virtual cell foundation model trained on ~40M cells (later scaled to ~200M) across many cancer indications. Simulates spatially resolved single-cell gene expression at arbitrary positions in real patient tissue, enabling high-fidelity prediction of thousands of genes in response to changes in biological context. Used to stratify patient populations and identify therapy resistance mechanisms (e.g., KRAS/STK11). Licensed to GSK under a five-year, $50M+ upfront non-exclusive license for NSCLC and CRC research.
  • TARIO-2 Multimodal AI foundation model that predicts patient response and survival outcomes to next-generation immune checkpoint inhibitor combinations (e.g., Agenus's BOT+BAL) using only routine pretreatment H&E pathology images. Trained on thousands of samples across 19 cancer types and paired with high-resolution spatial transcriptomics during training. Outperformed leading pathology AI tools in retrospective MSS mCRC validation (64% vs. 9% response rate; HR 0.18 for OS).
  • Perturb-map High-throughput in vivo perturbation platform that introduces hundreds of tumor subpopulations with unique mutations (suggested by Noetik's models) into a single mouse, then spatially resolves their impact on the tumor microenvironment. Used to validate AI-generated therapeutic hypotheses, study tumor-immune interactions, and map how mutations affect response to immune checkpoint blockade. Initial dataset maps >600 perturbations on tumor immunotypes.

Quantifiable outcome

  • 64% response rate vs 9% in remaining cohort for BOT+BAL in MSS mCRC (no active liver metastases), with overall survival hazard ratio of 0.18, in a retrospective study of 113 patients using TARIO-2 on routine pretreatment H&E images.
  • +4 more outcomes

Companies that use Noetik

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Noetik technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability8 records

Feature8 records

Noetik partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, flagship / anchor partnership and core / flagship.

  • Bruker Spatial BiologycoreTechnology or Integration · 24 February 2026Expansion of an existing collaboration to advance AI-driven tissue foundational models for translational and therapeutic applications in oncology. Builds on a prior study of more than 3,500 patient samples using Bruker's CosMx Spatial Molecular Imager, with Noetik now imaging thousands of additional patients to train its models toward one billion spatially resolved human cells. Supports Noetik's OCTO series and Oncology Counterfactual Therapeutics Oracle virtual cell models.
  • GSKflagship / anchor partnershipOEM/ Whitelabel/ Licensing Partner · 8 January 2026Five-year strategic collaboration and non-exclusive licensing agreement granting GSK access to Noetik's OCTO-VC virtual cell foundation models for non-small cell lung cancer (NSCLC) and colorectal cancer research. Deal valued at $50M upfront plus near-term milestones. Combines GSK's tumor immunology expertise with Noetik's spatial biology platform. Described as the first substantial pure-play AI licensing deal in the TechBio sector and a potential template for AI infrastructure licensing in biopharma. Noetik retains the right to license OCTO-VC to other drug developers.
  • Agenuscore / flagshipStrategic or Co-development Partner · 17 June 2025Research collaboration to develop AI-enabled predictive biomarkers for Agenus's botensilimab (BOT) and balstilimab (BAL) immuno-oncology treatments using Noetik's OCTO virtual cell foundation model (1.5B parameters, trained on multimodal spatial data from nearly 200M tumor and immune cells). Spans colorectal, lung, ovarian, and sarcoma cancers. Agenus receives exclusive rights to apply resulting biomarker insights in drug development and commercialization. Resulted in ASCO 2026 retrospective data showing 64% response rate vs 9% in TARIO-2-identified BOT+BAL subgroup in MSS mCRC without active liver metastases.
  • Khosla Ventures

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Noetik competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-native biotechnology company combining high-throughput biology with foundation-model-style ML to accelerate drug discovery. Noetik's two co-founders (Ron Alfa and Jacob Rinaldi) are both former Recursion leaders, making it the closest conceptual and operational analogue in the public TechBio space.
  • Insitro: ML-driven drug discovery company combining induced pluripotent stem cell biology with foundation models and large-scale data generation. Overlaps with Noetik in using proprietary wet-lab data to train ML models for oncology and other indications, and competes for similar pharma partnerships and talent.
  • Generate Biomedicines: Pioneer of generative biology foundation models that learn the language of proteins and apply it to therapeutic design. Directly comparable to Noetik's OCTO family of multimodal foundation models, and similarly targets pharma partnerships and internal therapeutics programs.
  • Owkin: AI-for-oncology and biopharma company that builds foundation models on multimodal patient data (pathology, omics, clinical) and partners with pharma on biomarker, stratification, and trial-enrichment use cases. Closely parallels Noetik's TARIO-2 thesis and pharma-licensing GTM.
  • Exscientia: AI-driven precision medicine company that combines generative chemistry with patient-derived data for drug design and selection. Comparable to Noetik in selling AI capabilities to large pharma partners and using data-driven approaches to oncology drug development.
  • PathAI: AI-pathology company that builds foundation models on histopathology images for biomarker discovery, patient stratification, and pharma partnerships. Closely mirrors Noetik's TARIO-2 image-based response prediction approach and pathology-AI focus.
  • Absci: Generative AI drug creation company combining foundation models for proteins with a high-throughput wet lab. Overlaps with Noetik in building proprietary data + foundation models to enable new therapeutics, and in pursuing both internal pipeline and pharma collaborations.
  • BenevolentAI: AI-drug discovery company that builds knowledge graphs and ML models to identify novel targets and indications, including in oncology. Comparable in combining AI/ML with pharma partnerships and pursuing precision-medicine applications in cancer.

Broad incumbents

  • Tempus Labs: Large, established AI-powered precision medicine company with massive multimodal oncology data (DNA, RNA, imaging, clinical) and extensive pharma services. A broad incumbent in the same oncology AI/data space Noetik targets, with a much larger scale and broader product portfolio.

Emerging players

  • Lantern Pharma: AI-driven oncology company using machine learning on genomic and clinical data to develop and reposition cancer therapies, with an emphasis on response prediction. Less capital-intensive than Noetik but pursues a similar AI-for-oncology-therapeutics thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Noetik social profiles

Digital presence

Noetik financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Noetik leadership team

Management profile

Number of profiles

Profiles13 records

Noetik funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Noetik M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noetik

What does Noetik do?

Noetik develops and licenses AI foundation models for oncology drug discovery, trained on proprietary in-house generated multimodal spatial omics datasets from thousands of patient tumors. Its core products (OCTO, OCTO-vc, TARIO-2) enable prediction of cancer patient treatment response, identification of novel therapeutic targets through counterfactual virtual cell simulations, and image-based patient stratification from routine H&E pathology slides. The company monetizes these models through multi-year enterprise licensing agreements with pharmaceutical and biotechnology companies, supported by an integrated wet-lab data factory and in vivo Perturb-map validation platform.

Is Noetik a public or private company?

Noetik is a private company. It is classified as venture growth investor backed and is currently operating.

When was Noetik founded?

Noetik was founded in 2023. It employs 51 to 100 people.

Where is Noetik based?

Noetik is headquartered in South San Francisco, United States, in the North America region.

How does Noetik make money?

Three revenue lines are on record. Foundation model licensing to pharma is the primary driver. The others are research collaboration and biomarker development and internal therapeutics pipeline (pre-revenue).

Who are Noetik's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Generate Biomedicines, Owkin, Exscientia, PathAI, Absci and BenevolentAI. Tempus Labs is listed as a broad incumbent. Lantern Pharma is listed as an emerging player.

Does Noetik have an API?

No public API is recorded for Noetik.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SynBioBetaNoetik Achieves First Milestone in Landmark GSK CollaborationNoetik achieved its first milestone under a five-year licensing agreement with GSK, delivering OCTO-VC model inference and fine-tuning capabilities. The milestone, announced September 1, 2026, follows a $50 million upfront payment and subscription-based access. GSK teams are using the models for virtual cell experiments and patient stratification.Business Wire BlogNoetik Achieves First Milestone in Landmark GSK CollaborationNoetik said it met the first near-term milestone under its five-year licensing agreement with GSK, triggered by delivering and deploying OCTO-VC model inference and fine-tuning capabilities. The deal, announced in January 2026, includes $50 million in upfront capital and ongoing subscription fees, with GSK holding a non-exclusive license to the models in NSCLC and colorectal cancer.BioSpaceNoetik Achieves First Milestone in Landmark GSK CollaborationNoetik met the first near-term milestone under its five-year licensing agreement with GSK, triggered by delivering OCTO-VC model inference and fine-tuning capabilities. The milestone is backed by $50 million in upfront capital and near-term payments, reinforcing Noetik's model-licensing approach as a recurring-revenue asset class.RdworldonlineNoetik’s TARIO-2: A ‘world model’ that reads a tumor from a single slideNoetik's TARIO-2 model predicts response to Agenus's colorectal cancer immunotherapy from a single H&E slide, ranking top 30% of patients at 64% response versus 9% for others. The model achieved an AUROC of 0.81, outperforming other H&E-only models, and Noetik has profiled over 5,000 patients.BioSpaceAgenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRCAgenus Inc. announced retrospective data from ASCO 2026 showing that Noetik's AI-based TARIO-2 model analyzed routine pretreatment H&E pathology images from 113 patients treated with botensilimab (BOT) plus balstilimab (BAL) to identify spatial tumor microenvironment patterns associated with clinical outcomes. In the MSS metastatic colorectal cancer without active liver metastases cohort, the AI-identified subgroup showed a 64% response rate compared with 9% in the remaining cohort, with a hazard ratio of 0.18 for overall survival. The findings support prospective validation of TARIO-2 as a practical, image-based biomarker strategy for patient stratification with BOT+BAL.Business Wire BlogAgenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRCAgenus and Noetik presented ASCO 2026 data showing AI analysis of routine pretreatment H&E images identified spatial tumor microenvironment patterns linked to BOT+BAL response and survival. In MSS metastatic colorectal cancer without active liver metastases, the AI-identified subgroup had a 64% response rate versus 9% in the remaining cohort, with median overall survival not reached and a hazard ratio of 0.18.DistilinfoBiology-Native Data Infrastructure Powers AI Drug DiscoveryIn June 2025, Insilico Medicine published positive Phase IIa results for rentosertib, the first drug where both target discovery and molecule design relied entirely on generative AI, achieving a preclinical candidate after screening just 78 molecules in 18 months at less than 10% of average cost per approved drug. Large pharmaceutical companies are responding by committing significant capital: GSK invested $50 million upfront in NOETIK while Eli Lilly agreed to pay a mid-eight-figure annual fee to Chai Discovery for biologics design access. The article argues that the competitive edge in AI drug discovery has shifted from model access to data infrastructure, citing three reinforcing principles—biology-native data at scale, agentic AI across R&D workflows, and closed-loop lab automation.Digital Health NewsGSK Partners with Noetik to Advance AI-Driven Cancer ResearchGSK has announced a $50 million upfront investment plus near-term milestones in a five-year strategic collaboration with San Francisco-based Noetik to access its AI-powered cancer research platform. The non-exclusive licensing agreement covers foundation AI models focused on non-small cell lung cancer and colorectal cancer, combining GSK's tumor immunology expertise with Noetik's virtual cell simulation technology to accelerate oncology drug discovery.GenengnewsPharma’s AI Investment Signals New Drug Discovery ParadigmGenerate:Biomedicines announced that GB-0895, the first AI-derived antibody, has entered Phase III clinical trials for severe asthma, having progressed from discovery to this milestone in just five years. The company recently completed one of the pharma sector's largest IPOs in years, raising $400 million to fund clinical development. Multiple major pharmaceutical collaborations were highlighted—including Bayer with Cradle, Eli Lilly with Chai Discovery, Pfizer with Boltz, and GSK with Noetik—signaling a broader industry shift toward AI-driven drug discovery infrastructure.LinkedInLinkedInThe provided text consists of multiple unrelated LinkedIn posts from the company Noetik, covering recent experiments on spatial biology foundation models, a five-year licensing agreement with GSK for cancer research, and presentations at the SITC Annual Meeting. The content does not form a single cohesive news article but rather a feed of corporate updates. As there is no single core event to summarize or analyze for impact, the structured output reflects this lack of a unified narrative.